Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL6 | P05231 | 8/20 | 0.47 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 4/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | STK10 | O94804 | 2/20 | 0.35 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4581043 | 0.94 | IL6 (0.47) | IL6CREBBPGRM5MAOBSTK10 | |
| SCHEMBL4580569 | 0.93 | IL6 (0.48) | IL6CREBBPGRM5STK10SLK | |
| SCHEMBL4581546 | 0.89 | IL6 (0.49) | IL6CREBBPMAOBKDM4EPOLB | |
| SCHEMBL4582029 | 0.87 | IL6 (0.56) | IL6CREBBP | |
| SCHEMBL4145214 | 0.87 | IL6 (0.46) | IL6GRM5STK10SLKKDM4E | |
| SCHEMBL4582246 | 0.83 | IL6 (0.50) | IL6CREBBP | |
| SCHEMBL4139669 | 0.83 | IL6 (0.46) | IL6CREBBP | |
| SCHEMBL4583021 | 0.83 | IL6 (0.69) | IL6CREBBPGRM5MAOBDAO | |
| SCHEMBL4140234 | 0.81 | IL6 (0.44) | IL6CREBBPKDM4EMAPTMAPK1 | |
| SCHEMBL4579668 | 0.80 | IL6 (0.43) | IL6CREBBPKDM4EPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975256-B2 | 1,2,3,4-tetrahydroquinoxaline compounds having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2015-03-10 | — | — | US | disclosed |
| US-8975256-B2 | 1,2,3,4-tetrahydroquinoxaline compounds having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2015-03-10 | — | — | US | disclosed |
| US-20130303537-A1 | 1,2,3,4-TETRAHYDROQUINOXALINE COMPOUNDS HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-11-14 | — | — | US | disclosed |
| US-8551991-B2 | 1,2,3,4-tetrahydroquinoxaline derivative having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| US-8551991-B2 | 1,2,3,4-tetrahydroquinoxaline derivative having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| EP-1995242-B1 | NOVEL 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY | SANTEN PHARMACEUTICAL CO LTD (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-20090111807-A1 | Novel 1,2,3,4-Tetrahydroquinoxaline Derivative Having Glucocorticoid Receptor Binding Activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-04-30 | — | — | US | disclosed |
| US-20090111807-A1 | Novel 1,2,3,4-Tetrahydroquinoxaline Derivative Having Glucocorticoid Receptor Binding Activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-04-30 | — | — | US | disclosed |
| EP-1995242-A1 | NOVEL 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY | Santen Pharmaceutical Co., Ltd (JP) | 2008-11-26 | — | — | EP | disclosed |
| EP-1995242-A1 | NOVEL 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY | Santen Pharmaceutical Co., Ltd (JP) | 2008-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303537-A1 | 1,2,3,4-TETRAHYDROQUINOXALINE COMPOUNDS HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY | NR3C1, NR3C2, NR5A1 | IL6 3798/4885CREBBP 1125/4885GRM5 62/4885 |
| US-20090111807-A1 | Novel 1,2,3,4-Tetrahydroquinoxaline Derivative Having Glucocorticoid Receptor Binding Activity | NR3C1, NR3C2, MC2R | IL6 3728/4885CREBBP 962/4885GRM5 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.